IMRN (Immuron) EBIT per Share : $-0.81 (TTM As of Jun. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Immuron EBIT per Share?

Immuron's EBIT per Share for the six months ended in Jun. 2024 was $-0.57. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2024 was $-0.81.

During the past 3 years, the average EBIT per Share Growth Rate was 13.90% per year. During the past 5 years, the average EBIT per Share Growth Rate was 8.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Immuron's EBIT per Share or its related term are showing as below:

IMRN' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -16.1 Med: 13.9 Max: 34.3
Current: 13.9

During the past 10 years, the highest 3-Year average EBIT per Share Growth Rate of Immuron was 34.30% per year. The lowest was -16.10% per year. And the median was 13.90% per year.

IMRN's 3-Year EBIT Growth Rate is ranked better than
65.89% of 1249 companies
in the Biotechnology industry
Industry Median: 2.8 vs IMRN: 13.90

Immuron's EBIT for the six months ended in Jun. 2024 was $-3.23 Mil.

Immuron EBIT per Share Historical Data

The historical data trend for Immuron's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immuron EBIT per Share Chart

Immuron Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

EBIT per Share

Get a 7-Day Free Trial

-0.46

-1.16

-0.35

-0.45

-0.81

Immuron Semi-Annual Data
	Jun15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
EBIT per Share	Get a 7-Day Free Trial													-0.13	-0.23	-0.21	-0.24	-0.57

Immuron EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Immuron's EBIT per Share for the fiscal year that ended in Jun. 2024 is calculated as

	EBIT per Share		(A: Jun. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-4.601	/	5.697
=	-0.81

Immuron's EBIT per Share for the quarter that ended in Jun. 2024 is calculated as

	EBIT per Share		(Q: Jun. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-3.227	/	5.698
=	-0.57

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.81

Immuron (NAS:IMRN) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Immuron EBIT per Share Related Terms

Thank you for viewing the detailed overview of Immuron's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Immuron Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuron Ltd (NAS:IMRN) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

ANWA:Germany ANWA:Germany ANW:Germany IMC:Australia

Address

Chapman Street, Unit 10, 25-37, Blackburn North, Melbourne, VIC, AUS, 3130

Website

https://www.immuron.com.au

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.